Company Profile
BioXcel Stock Price, News & Analysis
- Ticker:
- BTAI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.87 USD (+2.30%)
Close
Last updated: July 27, 2026
36.7M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, BTAI closed up 2.30% at $0.8670. No new same-company headline was identified in the current news window.
Company overview
Business overview
BioXcel Therapeutics is a neuroscience and immuno-oncology company focused on using artificial intelligence to identify therapeutic candidates. Its story combines data-driven discovery with development-stage biotech execution.
Geographic Base and Sector Classification
BioXcel is headquartered in the United States and listed on NASDAQ. It sits in neuroscience and platform biotechnology.
Business Model Characteristics
The company depends on clinical progress, platform validation, and the ability to turn AI-enabled discovery into real therapeutic value. Investors watch data, safety, and pipeline prioritization.
Position Within the Biotechnology Landscape
BioXcel occupies a platform-heavy neuroscience niche within biotech. The stock is driven by whether its AI-assisted approach can support a viable pipeline.
Future catalysts
BioXcel’s catalysts are IGALMI and the neuroscience pipeline, plus any strategic update that clarifies the company’s commercial path. The market will care about whether the product base can stabilize.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
DNLI · Source: Denali Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of BioXcel (BTAI)?
BioXcel (BTAI) most recently closed at 0.87 USD, a +2.30% move versus the previous session.
What is the market cap of BioXcel (BTAI)?
BioXcel currently has a market capitalization of 36.7M USD on BioPharmSignal.
What does BioXcel do?
BioXcel Therapeutics is a neuroscience and immuno-oncology company focused on using artificial intelligence to identify therapeutic candidates. Its story combines data-driven discovery with development-stage biotech execution.
On which exchange is BTAI stock listed?
BioXcel (BTAI) is associated with NASDAQ, United States, Biopharma.
What is BioXcel?
BioXcel’s catalysts are IGALMI and the neuroscience pipeline, plus any strategic update that clarifies the company’s commercial path.
Which conditions is BioXcel targeting with BioXcel?
BioXcel is associated with oncology, neuroscience based on its company overview and current catalyst commentary.
How does BioXcel describe recent progress with BioXcel?
BioXcel’s catalysts are IGALMI and the neuroscience pipeline, plus any strategic update that clarifies the company’s commercial path.
What is Therapeutics?
BioXcel Therapeutics is a neuroscience and immuno-oncology company focused on using artificial intelligence to identify therapeutic candidates.